Addressing Rising Cancer Incidence and Burden in Younger Populations

News
Podcast

Primary care physicians cannot afford to dismiss younger people who present with symptoms of cancer in the face of increasing cancer incidence, according to Monique Gary, DO, MSc, FACS.

Monique Gary, DO, MSc, FACS spoke with CancerNetwork® about estimated increases in cancer burden across the world and the potential rises in cancer inequities among underserved populations, and discussed mitigating these disparities from an oncology and primary care perspective.

Gary, a board-certified breast surgical oncologist and medical director of the Grand View Health/Penn Cancer Network cancer program, talked about growing cancer burden in the context of a World Health Organization (WHO) survey that projected future cancer risks. According to findings from the survey, there was an estimated 20 million new cancer cases and 9.7 million deaths from cancer in 2022. Authors estimated that 1 in 5 people will develop cancer, with 1 in 9 men and 1 in 12 women estimated to die from their disease. Additionally, more than 35 million new cancer cases were projected in 2050, representing a 77% increase from the estimated 20 million cases in 2022.

In particular, Gary highlighted a rise in cancer diagnoses among younger patients, including those without family history or hereditary mutations. In addition to environmental factors such as poor air quality and health conditions like obesity, she emphasized health system inequities in certain countries as obstacles that may contribute to rising cancer burden. Due to a lack of financial protection, some patients may lack adequate access to early detection and therapy for cancer.

Part of addressing these inequities, Gary said, requires primary care physicians redefining their perspective of cancer and not dismissing younger people who present with cancer symptoms. In addition to increasing screening for younger populations, she stated that it was necessary for oncologists to lean into available research and encourage patients to enroll on clinical trials.

“It's not just the job of advocacy groups and societies; it's the job of every clinician,” Gary said regarding what needed to be done to address the growth in cancer incidence and disparities. “The individuals who have been disadvantaged already, those [patients] who have a higher mortality and are diagnosed at a later stage of disease…don't have the access. This disparity is going to get wider and wider; we'll do something about it. And that should inspire everyone because there's something for everyone to do.”

Reference

World Health Organization. Global cancer burden growing, amidst mounting need for services. February 1, 2024. Accessed March 5, 2024. https://shorturl.at/pLNU7

Recent Videos
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
Patients who face smoking stigma, perceive a lack of insurance, or have other low-dose CT related concerns may benefit from blood testing for lung cancer.
The Together for Supportive Cancer Care coalition may advance the national conversation in ensuring comprehensive care for all patients with cancer.
Health care organizations have come together to form the Together for Supportive Cancer Care coalition to address gaps in supportive cancer care services.
Further optimizing a PROTAC that targets MDM2 may lead to human clinical trials among patients with cancer harboring p53 mutations.
Subsequent testing among patients in a prospective study may affirm the ability of cfDNA sequencing to detect cancers in those with Li-Fraumeni syndrome.
cfDNA sequencing may allow for more accessible, frequent, and sensitive testing compared with standard surveillance in Li-Fraumeni syndrome.
STX-478 showed efficacy in patients with advanced solid tumors regardless of whether they had kinase domain or helical PI3K mutations.